SCHEMBL25414829

SCHEMBL25414829

Cc1cc(C(C)Nc2ccccc2C(=O)O)c2nc(N3CCC(C)(C)CC3)cc(=O)n2c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.82
AKT1 P31749 9/20 0.82
AKT2 P31751 9/20 0.82
AKT3 Q9Y243 9/20 0.82
PIK3CB P42338 11/20 0.80
PIK3CD O00329 3/20 0.80
PIK3CG P48736 3/20 0.80
SRC P12931 1/20 0.80
DDX6 P26196 1/20 0.80
PDE4A P27815 1/20 0.80
CSK P41240 1/20 0.80
MTOR P42345 1/20 0.80
PLK1 P53350 1/20 0.80
PRKDC P78527 1/20 0.80
PDE4B Q07343 1/20 0.80
PDE4C Q08493 1/20 0.80
PDE4D Q08499 1/20 0.80
AURKB Q96GD4 1/20 0.80
PI4KB Q9UBF8 1/20 0.80
HDAC6 Q9UBN7 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25414825 1.00 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL26136960 1.00 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL30780741 1.00 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL27116441 0.94 PIK3CA (0.84) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL26136962 0.94 PIK3CA (0.84) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL30780666 0.94 PIK3CA (0.84) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL26136961 0.94 PIK3CA (0.84) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL25415277 0.93 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL25415273 0.93 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB
SCHEMBL26137362 0.93 PIK3CA (0.82) PIK3CAAKT1AKT2AKT3PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2026-03-19 US claimed
EP-4577544-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2025-07-02 EP claimed
WO-2024044769-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2024-02-29 WO claimed
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2026-03-19 US disclosed
EP-4577544-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2025-07-02 EP disclosed
WO-2024044769-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2024-02-29 WO disclosed
WO-2023078401-A1 COMPOUNDS AS PROTEIN KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-11 WO disclosed
WO-2023081209-A1 PI3K INHIBITORS AND METHODS OF TREATING CANCER ZENO MANAGEMENT, INC. (US) 2023-05-11 WO disclosed
WO-2023081209-A1 PI3K INHIBITORS AND METHODS OF TREATING CANCER ZENO MANAGEMENT, INC. (US) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES CBR1, CBR3, CNR1 PIK3CA 2749/4885AKT1 2105/4885AKT2 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.